Irsogladine
| |
| Names | |
|---|---|
| Preferred IUPAC name 6-(2,5-Dichlorophenyl)1,3,5-triazine-2,4-diamine | |
| Other names DCPDAT, Dicloguamine, MN-1695. | |
| Identifiers | |
| ChemSpider | |
PubChem CID |
|
| UNII | |
CompTox Dashboard (EPA) |
|
| Properties | |
| C9H7Cl2N5 | |
| Molar mass | 256.09 g·mol−1 |
| Pharmacology | |
| A02BX16 (WHO) | |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). | |
Irsogladine is a phosphodiesterase inhibitor.[1]
Antiulcer drug.
Synthesis
2,4-Dichloro-6-(2,5-dichlorophenyl)-1,3,5-triazine [61479-79-6] (1) (2) Dicyandiamide [461-58-5] (3) 2,5-Dichlorobenzonitrile [21663-61-6] (4)
References
- ^ Satoh, H; Amagase, K; Takeuchi, K (2013). "Mucosal protective agents prevent exacerbation of NSAID-induced small intestinal lesions caused by antisecretory drugs in rats". The Journal of Pharmacology and Experimental Therapeutics. 348 (2): 227–35. doi:10.1124/jpet.113.208991. PMID 24254524. S2CID 23740642.
- ^ Serradell, MN; Blancafort, P.; Castaer, J.; MN-1695. Drugs Fut 1983, 8, 6, 502.
- ^ Ueda F, Aratani S, Mimura K, Kimura K, Nomura A, Enomoto H. Effect of 2,4-diamino-6-(2,5-dichlorophenyl)-s-triazine maleate (MN-1695) on gastric ulcers and gastric secretion in experimental animals. Arzneimittelforschung. 1984;34(4):474-7. PMID: 654016.
- ^ DE2506814 idem Hiromu Murai, 6 More », U.S. patent 3,966,728 (1976 to Nippon Shinyaku Co., Ltd.).
